Environmental, Social, and Governance (ESG)

Building a Responsible Future in Pharma

At MMS, our commitment to excellence extends beyond drug development. As an award-winning, data-focused CRO, we recognize our responsibility to contribute to a sustainable, ethical, and socially responsible future. Our ESG strategy is integral to our mission to positively improve patient’s lives globally, and it guides us in every aspect of our operations and partnerships.

Environmental Responsibility

We are dedicated to minimizing the environmental footprint of MMS and promoting sustainable practices across all our operations around the world. We proactively seek to reduce energy consumption, manage waste responsibly, and support environmental initiatives internally and in the communities where we live and work.

By leveraging technology and data-driven solutions, we optimize our processes to ensure efficiency and sustainability, including:

  • Green Facilities: We are committed to maintaining eco-friendly offices, implementing energy-saving methodologies and technologies, as well as reducing our reliance on non-renewable resources.
  • Sustainable Operations: Through continuous monitoring and assessment, we identify areas where MMS colleagues can reduce waste, recycle materials, and minimize our impact on the environment.
  • Collaborative Initiatives: We partner with like-minded organizations to advance environmental sustainability in clinical research, aiming for a higher standard.
Social Impact

Our success is intertwined with the well-being of the communities we serve and the experts that we employ. MMS fosters an inclusive and supportive workplace to drive positive change for individual stakeholders, partners, sponsors, and ultimately the public through the outcomes from our work.

This includes the following:

  • Diversity, Equity, and Inclusion: MMS is committed to maintaining a diverse and inclusive environment where all employees feel valued and empowered to contribute their best. Our DEI initiatives are embedded in our recruitment, training, and continuous leadership development programs.
  • Community Engagement: We actively engage with the local communities that we operate in, through individual and company-led volunteer efforts and other initiatives. Our team members are given time during the workday to volunteer and MMS provides resources to amplify their impact.
  • Patient-Centric Outcomes: Our work with sponsors prioritizes patient safety, transparency, and accessibility. We strive to ensure that our support of drug development programs across nearly all therapeutic areas maintain high ethical and scientific standards, allowing the results to have a meaningful contribution to public health.
Governance Excellence

MMS is guided by a strong governance framework that ensures clarity and accountability at all levels of the organization globally. Our governance practices are designed to protect the interests of our stakeholders, including:

  • Ethical Standards: We adhere to the highest ethical standards across all projects and business practices. This ensures that all activities are conducted with integrity and respect for the regulatory requirements set by global health authorities.
  • Transparent Reporting: We are committed to providing clear and accurate reporting on our ESG initiatives, demonstrating our progress and areas for improvement. This allows us to build further trust with our stakeholders and reinforce our commitment to accountability.
  • Continuous Improvement: Our governance framework is dynamic, changing as pharmaceutical industry best practices evolve and stakeholder expectations heighten. We regularly review and enhance our policies and procedures to ensure they align with our ESG goals.
Our Commitment

MMS is proud to be at the forefront of integrating ESG principles into our #OneMMS ecosystem. We understand that our work has a far-reaching impact. This motivates every decision that we make, and we are dedicated to making a positive difference in the world.

By prioritizing sustainability, social responsibility, and strong governance, we are building a future that benefits all. Join MMS on our journey and message us with any questions that you may have.

Suggested For You

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar